GlobeNewswire Inc.··Muscular Dystrophy AssociationFDA Expands VYVGART Approval to All Generalized Myasthenia Gravis Patients
FDA expands VYVGART approval to include seronegative myasthenia gravis patients, broadening treatment access and increasing commercial opportunity for Ultragenyx.
ARGXFDA approvalclinical trial